IL-17A needs to bind with its receptor complex, including IL-17RA and IL-17RC, and further activate downstream pathways to achieve its biological effects, such as promoting invasion in NSCLC cells [37]. The gene discussed is IL17RA; the disease is non-small cell lung carcinoma.